During the 61st American Society of Hematology (ASH) meeting in Orlando, US, the AML Global Portal was delighted to speak to Selina Luger, University of Pennsylvania, Philadelphia, US. We asked: Could aspacytarabine be a new option for first-line therapy in patients with acute myeloid leukemia that are unfit for intensive chemotherapy?
Selina Luger explains that aspacytarabine, a cytarabine derivative, is effective and less toxic than cytarabine. Based on recent data, aspacytarabine is safe and efficacious for the treatment of AML patients who are unfit for standard chemotherapy.